If Boston Scientific Corp. wins its battle royal with Johnson & Johnson over Guidant Corp., the company will owe a big debt to Abbott Laboratories, and not just a debt of gratitude.
Guidant said Tuesday, it favors Boston Scientific’s latest bid, $80 per share tendered Tuesday morning. That trumps J&J’s $71 per share. The declaration is not the same as acceptance: It has until Jan. 25 to consider the bid.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
